Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Matrix III Carboplatin
- Development stage
- Preclinical
- Lead developer
- Royer Biomedical
- Modality
- Small Molecules, Drug Delivery Systems
- Administration
- Localized, Implantation
01
Overview
Matrix III Carboplatin is a localized, controlled-release formulation of the platinum-based cytotoxic agent carboplatin, developed by Royer Biomedical. It utilizes a calcium-based matrix (Matrix III platform) to deliver the drug directly to tumor sites, concentrating the therapeutic effect while minimizing systemic toxicity. This delivery system is specifically being developed for the treatment of various feline cancers. Carboplatin works by binding to DNA, causing inter- and intra-strand cross-links that inhibit DNA synthesis and lead to apoptosis in rapidly dividing cancer cells.
- Other names
- carboplatin
02
Targets
DNA
Beyond the preview
Go deeper on Matrix III Carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Matrix III Carboplatin.